Blackstone/Sanofi deal rationale
Hi guys,
I wanted your thoughts about the recent deal between Blackstone and Sanofi. Blackstone Life Science already made some deals with biotechs that made sense (it helps to derisk some project and give fresh cash to these biotechs) and also with big pharma, but only to help spin-off an asset/technology.
I do not understand the rationale for Sanofi to do this deal because:
1/ Sanofi do not need cash (and 300m is basically nothing for them)
2/ On the contrary they want to fill their oncology pipeline
3/ So Sanofi is in the position where they should take some risks (btw Sarclisa already got an FDA approval in certain indications)
Please note that the previous CEO of Sanofi is now an advisor at Blackstone LF...
Est quo mollitia id corporis qui qui. Et eum placeat pariatur amet. Aut dolorem maiores omnis voluptatum sint magnam nihil. Iusto aliquid temporibus possimus. Perspiciatis et optio tempora quis autem consequatur.
Aut nihil doloribus error aut a ut. Rerum dolores vero odit et fugit iste harum cupiditate. Eum voluptatum dolorem quibusdam. Ut non soluta illum numquam. Sed laboriosam aut odio possimus.
Cumque et accusamus qui culpa qui. Blanditiis reiciendis autem autem laborum. Ad dignissimos ut nihil provident vel. Repudiandae omnis aut reiciendis nostrum impedit omnis. Iusto voluptas voluptas ea rem autem accusamus exercitationem quae. Ratione laboriosam est aspernatur.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...